| abstract |
Method for the treatment of a condition or disease selected from the group consisting of hypertension, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiomyopathy, superventricular and ventricular arrhythmias, atrial fibrillation, atrial vibration, damaging vascular remodeling, myocardial infarction and its sequelae , atherosclerosis, angina (either unstable or stable), renal failure (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal insufficiency conditions, such as diabetic nephropathy, glomerulonephritis , scleroderma, glomerular sclerosis, proteinuria of primary renal disease, and also renal vascular hypertension, diabetic retinopathy, the management of other vascular disorders, such as migraine, peripheral vasculopathy, Raynaud's disease, luminal hyperplasia, endothelial dysfunction l, cognitive dysfunction (such as Alzheimer's), glaucoma and embolism, which comprises administering, to a mammal in need, a therapeutically effective amount of a combination comprising: (i) an angiotensin-converting enzyme (ACE) inhibitor , (ii) a calcium channel blocker (CCB), and (iii) a diuretic. Claim 5: A method according to claim 1, a composition according to claim 2, or a kit of parts according to claim 3, wherein the angiotensin converting enzyme inhibitor (i) is benazepril or benazeprilat , the calcium channel blocker (ii) is amlodipine, and the diuretic (iii) is hydrochlorothiazide. |